Overview

Sirolimus in COVID-19 Phase 1

Status:
Withdrawn
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a double-blinded, two-arm, randomized, placebo controlled study comparing the virological efficacy of add-on sirolimus with standard care to placebo and standard care. Virological efficacy is defined as the change from baseline to day 7 in SARS-CoV-2 viral burden measured by quantitative real-time polymerase chain reaction.
Phase:
Phase 1
Details
Lead Sponsor:
Walter K. Kraft
Treatments:
Sirolimus